Literature DB >> 18753635

Overcoming obstacles to the effective immunotherapy of human cancer.

Steven A Rosenberg1.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18753635      PMCID： PMC2529039          DOI： 10.1073/pnas.0806877105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  20 in total

1.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

Review 2.  Adoptive immunotherapy for cancer: building on success.

Authors:  Luca Gattinoni; Daniel J Powell; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

Review 3.  Checkpoint blockade in cancer immunotherapy.

Authors:  Alan J Korman; Karl S Peggs; James P Allison
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

Review 4.  Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression.

Authors:  Paolo Serafini; Ivan Borrello; Vincenzo Bronte
Journal:  Semin Cancer Biol       Date:  2005-09-15       Impact factor: 15.707

5.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

6.  Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.

Authors:  Steven A Rosenberg; Richard M Sherry; Kathleen E Morton; William J Scharfman; James C Yang; Suzanne L Topalian; Richard E Royal; Udai Kammula; Nicholas P Restifo; Marybeth S Hughes; Douglas Schwartzentruber; David M Berman; Susan L Schwarz; Lien T Ngo; Sharon A Mavroukakis; Donald E White; Seth M Steinberg
Journal:  J Immunol       Date:  2005-11-01       Impact factor: 5.422

Review 7.  Transforming growth factor-beta and the immune response: implications for anticancer therapy.

Authors:  Stephen H Wrzesinski; Yisong Y Wan; Richard A Flavell
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

Review 8.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy.

Authors:  Steven A Rosenberg; Nicholas P Restifo; James C Yang; Richard A Morgan; Mark E Dudley
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

Review 9.  Strategies for use of IL-10 or its antagonists in human disease.

Authors:  Anne O'Garra; Franck J Barrat; Antonio G Castro; Alain Vicari; Catherine Hawrylowicz
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

10.  Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice.

Authors:  Ailin Bai; Eileen Higham; Herman N Eisen; K Dane Wittrup; Jianzhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-22       Impact factor: 11.205
View more
  19 in total

Review 1.  Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells.

Authors:  F M Hofman; A Stathopoulos; C A Kruse; T C Chen; V E J C Schijns
Journal:  Anticancer Agents Med Chem       Date:  2010-07       Impact factor: 2.505

2.  Host b7x promotes pulmonary metastasis of breast cancer.

Authors:  Yael M Abadi; Hyungjun Jeon; Kim C Ohaegbulam; Lisa Scandiuzzi; Kaya Ghosh; Kimberly A Hofmeyer; Jun Sik Lee; Anjana Ray; Claudia Gravekamp; Xingxing Zang
Journal:  J Immunol       Date:  2013-03-01       Impact factor: 5.422

3.  A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin.

Authors:  Salvatore Fiorenza; Tony J Kenna; Iain Comerford; Shaun McColl; Raymond J Steptoe; Graham R Leggatt; Ian H Frazer
Journal:  J Immunol       Date:  2012-11-09       Impact factor: 5.422

4.  EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice.

Authors:  Alexei Shir; Manfred Ogris; Wolfgang Roedl; Ernst Wagner; Alexander Levitzki
Journal:  Clin Cancer Res       Date:  2010-12-30       Impact factor: 12.531

Review 5.  Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma.

Authors:  Christopher Schutt; Klaus Bumm; Leonardo Mirandola; Giovanni Bernardini; Nicholas D' Cunha; Lukman Tijani; Diane Nguyen; Joehassin Cordero; Marjorie R Jenkins; Everardo Cobos; W Martin Kast; Maurizio Chiriva-Internati
Journal:  Int Rev Immunol       Date:  2012-02       Impact factor: 5.311

6.  High-avidity T cells are preferentially tolerized in the tumor microenvironment.

Authors:  Ziqiang Zhu; Vinod Singh; Stephanie K Watkins; Vincenzo Bronte; Jennifer L Shoe; Lionel Feigenbaum; Arthur A Hurwitz
Journal:  Cancer Res       Date:  2012-11-30       Impact factor: 12.701

Review 7.  Immunotherapeutic approaches for glioma.

Authors:  Hideho Okada; Gary Kohanbash; Xinmei Zhu; Edward R Kastenhuber; Aki Hoji; Ryo Ueda; Mitsugu Fujita
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

Review 8.  Antiangiogenic therapy improves the antitumor effect of adoptive cell immunotherapy by normalizing tumor vasculature.

Authors:  Shujing Shi; Longbang Chen; Guichun Huang
Journal:  Med Oncol       Date:  2013-08-28       Impact factor: 3.064

9.  Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.

Authors:  Joseph I Clark; James Moon; Laura F Hutchins; Jeffrey A Sosman; W Martin Kast; Diane M Da Silva; P Y Liu; John A Thompson; Lawrence E Flaherty; Vernon K Sondak
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

Review 10.  Progress and challenges in the vaccine-based treatment of head and neck cancers.

Authors:  Aldo Venuti
Journal:  J Exp Clin Cancer Res       Date:  2009-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.